
Ocugen, Inc. (OCGN) Stock Forecast & Price Target
Ocugen, Inc. (OCGN) Analyst Ratings
Bulls say
Ocugen is a company focused on developing novel gene and cell therapies and vaccines to improve health for patients worldwide. Their pipeline includes potential treatments for various retinal diseases, such as inherited retinal diseases and age-related macular degeneration, as well as a potential COVID-19 vaccine. In March 2026, the company presented positive topline data from their Phase 2 ArMaDa study for their potential gene therapy for geographic atrophy (GA), with plans to initiate a Phase 3 study in 3Q26. With strong efficacy and safety data, as well as an expected launch in 2029, Ocugen's current stock price is expected to increase to $10.00 per diluted share.
Bears say
Ocugen is a high-risk investment due to its relatively small size and uncertainties surrounding its ability to successfully bring its products to market, making it a risky choice for investors. Additionally, the company's financials show a history of losses and negative cash flows, further highlighting the potential risks involved in investing in Ocugen.
This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.
Ocugen, Inc. (OCGN) Analyst Forecast & Price Prediction
Start investing in Ocugen, Inc. (OCGN)
Order type
Buy in
Order amount
Est. shares
0 shares